Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company advancing novel therapies targeting metabolic and fibrotic diseases through selective FASN inhibition. This page provides investors and industry stakeholders with timely updates on clinical trials, regulatory milestones, and strategic developments related to its lead candidate denifanstat and broader pipeline.
Access centralized, verified information on Sagimet’s progress in addressing metabolic dysfunction-associated steatohepatitis (MASH) and other conditions driven by abnormal lipid synthesis. Key updates include trial results, partnership announcements, and scientific advancements, all curated to support informed decision-making.
Explore press releases covering critical topics such as Phase 2b FASCINATE-2 trial outcomes, licensing agreements, and research innovations. Content is rigorously vetted to ensure accuracy and relevance for both professional analysts and engaged public audiences.
Bookmark this page for streamlined access to Sagimet’s latest developments in FASN inhibitor research. Check back regularly for authoritative updates on one of biopharma’s most promising approaches to metabolic disease treatment.
Sagimet Biosciences, a clinical-stage biopharmaceutical company, announced a conference call and webcast on June 13, 2024, at 9:30 AM PT / 12:30 PM ET to discuss data from their Phase 2b FASCINATE-2 clinical trial.
The trial evaluates denifanstat, an oral, once-daily FASN inhibitor, in metabolic dysfunction-associated steatohepatitis (MASH) patients. Dr. Rohit Loomba will present the data, which was recently shared at the EASL Congress in Milan, Italy.
Participants can join the live event via webcast or dial-in using provided numbers. A chat-based Q&A session will follow the presentation.
Sagimet Biosciences presented promising data from the Phase 2b FASCINATE-2 clinical trial of denifanstat at EASL 2024. Denifanstat significantly improved liver fibrosis and MASH resolution in patients with metabolic dysfunction-associated steatohepatitis (MASH), achieving primary and secondary endpoints.
Key results: 38% of denifanstat patients had a ≥2-point reduction in NAS without worsening fibrosis, compared to 16% for placebo. For fibrosis improvement by ≥1 stage without worsening MASH, results were 30% for denifanstat vs 14% for placebo. Denifanstat was well tolerated with no serious adverse events.
Based on these findings, Sagimet plans to initiate a Phase 3 registrational program for denifanstat in MASH with fibrosis in the latter half of 2024.
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, will host a virtual investor and analyst day on May 23, 2024, at 1:00 PM ET.
The event will feature Dr. Scott Friedman from Icahn School of Medicine at Mount Sinai, who will discuss the unmet needs and treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the event will cover topline data from Sagimet's FASCINATE-2 Phase 2b clinical trial for its lead drug candidate, denifanstat, an oral FASN inhibitor. A live Q&A session will follow the presentation.
Sagimet Biosciences (Nasdaq: SGMT) reported its Q1 2024 financial results, highlighting significant progress in the development of denifanstat for metabolic dysfunction-associated steatohepatitis (MASH). The company announced positive results from the Phase 2b FASCINATE-2 trial, meeting primary efficacy endpoints and demonstrating significant fibrosis reduction. Full trial results will be presented at the EASL Congress in June 2024. Sagimet plans a Phase 3 trial following an FDA meeting in Q2 2024. The company raised $104.7 million from a public offering and holds $193.7 million in cash as of March 31, 2024, ensuring a cash runway through 2025. Research and development expenses increased to $5.3 million, while net losses remained consistent at $6.6 million year-over-year.
Sagimet Biosciences Inc. announced the oral presentation of denifanstat Phase 2b FASCINATE-2 study data at the EASL International Liver Congress 2024. The study demonstrated significant fibrosis improvement and MASH resolution in patients with F2 or F3 fibrosis.
Sagimet Biosciences Inc. announced the appointment of Thierry Chauche as Chief Financial Officer. Chauche brings over 20 years of financial and biopharma experience to the role. The company granted him an inducement stock option worth $2 million. Additionally, Sagimet approved inducement grants of stock options for four other newly-hired employees.
FAQ
What is the current stock price of Sagimet Biosciences (SGMT)?
What is the market cap of Sagimet Biosciences (SGMT)?
